share_log

HSBC Initiates Coverage On Teva Pharmaceutical Indus With Buy Rating, Announces Price Target of $13

HSBC Initiates Coverage On Teva Pharmaceutical Indus With Buy Rating, Announces Price Target of $13

汇丰银行以买入评级启动对梯瓦制药行业的报道,宣布目标股价为13美元
Benzinga ·  2023/12/18 08:07

HSBC analyst Rajesh Kumar initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy rating and announces Price Target of $13.

汇丰银行分析师拉杰什·库马尔以买入评级开始对梯瓦制药工业公司(纽约证券交易所代码:TEVA)进行报道,并宣布目标股价为13美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发